COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.
COVID-19
SARS-CoV-2
advocacy
infectious disease prevention
neurological disorders
vaccination
vaccine skepticism
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
12
04
2022
accepted:
15
04
2022
pubmed:
24
4
2022
medline:
19
7
2022
entrez:
23
4
2022
Statut:
ppublish
Résumé
Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course. In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation. The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction. The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.
Sections du résumé
BACKGROUND AND PURPOSE
Health risks associated with SARS-CoV-2 infection are undisputed. Moreover, the capability of vaccination to prevent symptomatic, severe, and fatal COVID-19 is recognized. There is also early evidence that vaccination can reduce the chance for long COVID-19. Nonetheless, the willingness to get vaccinated and receive booster shots remains subpar among people with neurologic disorders. Vaccine scepticism not only jeopardizes collective efforts to end the COVID-19 pandemic but puts individual lives at risk, as some chronic neurologic diseases are associated with a higher risk for an unfavorable COVID-19 course.
METHODS
In this position paper, the NeuroCOVID-19 Task Force of the European Academy of Neurology (EAN) summarizes the current knowledge on the prognosis of COVID-19 among patients with neurologic disease, elucidates potential barriers to vaccination coverage, and formulates strategies to overcome vaccination hesitancy. A survey among the Task Force members on the phenomenon of vaccination hesitancy among people with neurologic disease supports the lines of argumentation.
RESULTS
The study revealed that people with multiple sclerosis and other nervous system autoimmune disorders are most skeptical of SARS-CoV-2 vaccination. The prevailing concerns included the chance of worsening the pre-existing neurological condition, vaccination-related adverse events, and drug interaction.
CONCLUSIONS
The EAN NeuroCOVID-19 Task Force reinforces the key role of neurologists as advocates of COVID-19 vaccination. Neurologists need to argue in the interest of their patients about the overwhelming individual and global benefits of COVID-19 vaccination. Moreover, they need to keep on eye on this vulnerable patient group, its concerns, and the emergence of potential safety signals.
Identifiants
pubmed: 35460319
doi: 10.1111/ene.15368
pmc: PMC9111566
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2163-2172Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Lancet Neurol. 2020 Oct;19(10):805-806
pubmed: 32949535
J Parkinsons Dis. 2021;11(1):3-8
pubmed: 33523021
Vaccines (Basel). 2021 Dec 11;9(12):
pubmed: 34960216
J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):339-340
pubmed: 34408004
Eur J Neurol. 2021 Nov;28(11):3849-3855
pubmed: 33460486
N Engl J Med. 2022 Mar 10;386(10):933-941
pubmed: 35020982
Front Neurol. 2020 Jul 07;11:781
pubmed: 32733373
Eur J Neurol. 2021 Oct;28(10):3418-3425
pubmed: 34080271
Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5542-5546
pubmed: 34533804
J Neuroimmunol. 2022 Jan 15;362:577765
pubmed: 34839149
Nat Commun. 2021 Oct 29;12(1):6238
pubmed: 34716349
Acta Biomed. 2021 Oct 19;92(S6):e2021472
pubmed: 34739454
Mult Scler Relat Disord. 2021 Jul;52:102939
pubmed: 34010764
Vaccine. 2019 Jan 7;37(2):226-234
pubmed: 30527660
Eur J Neurol. 2021 Jan;28(1):7-14
pubmed: 33058321
Epidemiol Infect. 2021 Feb 15;149:e66
pubmed: 33583450
J Neurol. 2021 Mar;268(3):762-769
pubmed: 32749601
Acta Neurol Scand. 2022 Apr;145(4):393-398
pubmed: 34967005
JAMA. 2020 Jun 23;323(24):2458-2459
pubmed: 32421155
Med (N Y). 2021 May 14;2(5):498-501
pubmed: 33851144
Blood. 2021 Dec 2;138(22):2256-2268
pubmed: 34587242
Nat Med. 2021 Dec;27(12):2144-2153
pubmed: 34697502
Neurol Int. 2021 Dec 06;13(4):695-700
pubmed: 34940752
JMIR Public Health Surveill. 2021 Nov 17;7(11):e30642
pubmed: 34653016
Mult Scler. 2021 May;27(6):864-870
pubmed: 33856242
Nat Med. 2021 Aug;27(8):1338-1339
pubmed: 34272500
Semin Thromb Hemost. 2022 Feb;48(1):8-14
pubmed: 34695859
Eur J Neurol. 2022 Feb;29(2):555-563
pubmed: 34668274
Front Neurol. 2021 Aug 10;12:721502
pubmed: 34447349
Vaccine. 2021 Apr 28;39(18):2517-2525
pubmed: 33824037
J Neurol. 2022 May;269(5):2275-2285
pubmed: 34984514
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
Patient Educ Couns. 2022 Feb;105(2):331-338
pubmed: 34090717
EBioMedicine. 2021 Dec;74:103692
pubmed: 34773893
Front Neurol. 2021 Oct 22;12:765954
pubmed: 34744992
Vaccine. 2015 Aug 14;33(34):4176-9
pubmed: 25896376
Lancet. 2022 Jan 15;399(10321):220-222
pubmed: 34953527
Neurol Sci. 2022 Jan;43(1):3-40
pubmed: 34719776
Front Neurol. 2021 Oct 05;12:743110
pubmed: 34675874
N Engl J Med. 2022 May 19;386(20):1910-1921
pubmed: 35320659
Epilepsia. 2022 Jan;63(1):244-251
pubmed: 34806164
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018
pubmed: 34982465
Mult Scler Relat Disord. 2021 Jun;51:102880
pubmed: 33740481
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):448-450
pubmed: 34408003
Eur Stroke J. 2021 Sep;6(3):CXVI-CXXI
pubmed: 34746428
Mult Scler Relat Disord. 2021 Nov;56:103236
pubmed: 34507240
Eur J Neurol. 2021 Oct;28(10):3226-3229
pubmed: 33386655
J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1033-1043
pubmed: 34353858
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):121-128
pubmed: 34836608
BMJ. 2021 May 20;373:n1138
pubmed: 34016653
J Parkinsons Dis. 2021;11(3):1057-1065
pubmed: 33935103
Eur J Neurol. 2020 Sep;27(9):1727-1737
pubmed: 32558002
Int J Environ Res Public Health. 2021 Apr 20;18(8):
pubmed: 33924140
J R Coll Physicians Edinb. 2021 Dec;51(4):330-331
pubmed: 34882128
Mult Scler Relat Disord. 2022 Jan;57:103433
pubmed: 34923427
Epilepsy Behav. 2021 Dec;125:108437
pubmed: 34839246
Front Neurol. 2021 Nov 17;12:778618
pubmed: 34867767
Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):
pubmed: 34544881
Arch Gerontol Geriatr. 2021 Mar-Apr;93:104299
pubmed: 33285424
Vaccines (Basel). 2021 Jan 28;9(2):
pubmed: 33525459
Eur J Neurol. 2022 Aug;29(8):2163-2172
pubmed: 35460319
Mult Scler Relat Disord. 2021 Sep;54:103163
pubmed: 34325399
EBioMedicine. 2021 Nov;73:103635
pubmed: 34656879